The patients with high disease activity at the start of RTX have previously failed at least one TNF inhibitor or other biologics (Table 1) and possibly represents a subgroup of “difficult to treat” RA patients not tolerating or not responding to currently available treatment modalities. This evidence concerns the gene TNF and rheumatoid arthritis.